Chiron Pulminiq "Approvable" Pending Confirmatory Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
An additional clinical trial is necessary to confirm the efficacy of Chiron’s Pulminiq inhaled immunosuppressant for prevention of lung transplant rejection, according to an FDA "approvable" letter received July 14.